Your browser doesn't support javascript.
loading
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place, Andrew E; Pikman, Yana; Stevenson, Kristen E; Harris, Marian H; Pauly, Melinda; Sulis, Maria-Luisa; Hijiya, Nobuko; Gore, Lia; Cooper, Todd M; Loh, Mignon L; Roti, Giovanni; Neuberg, Donna S; Hunt, Sarah K; Orloff-Parry, Sarah; Stegmaier, Kimberly; Sallan, Stephen E; Silverman, Lewis B.
  • Place AE; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Stevenson KE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Harris MH; Department of Pathology, Boston Children's Hospital, Boston, Massachusetts.
  • Pauly M; Department of Pediatrics, Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, Georgia.
  • Sulis ML; Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University, New York City, New York.
  • Hijiya N; Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital/Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Gore L; Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado.
  • Cooper TM; Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington.
  • Loh ML; Department of Pediatrics, Benioff Children's Hospital, University of California at San Francisco, San Francisco, California.
  • Roti G; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Neuberg DS; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hunt SK; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Orloff-Parry S; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Sallan SE; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
  • Silverman LB; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
Pediatr Blood Cancer ; 65(7): e27062, 2018 07.
Article en En | MEDLINE | ID: mdl-29603593
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Leucemia-Linfoma Linfoblástico de Células Precursoras / Everolimus / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Leucemia-Linfoma Linfoblástico de Células Precursoras / Everolimus / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Año: 2018 Tipo del documento: Article